Nanobody against PDL1

Biotechnol Lett. 2020 May;42(5):727-736. doi: 10.1007/s10529-020-02823-2. Epub 2020 Jan 31.

Abstract

Programmed death ligand 1 (PDL1, CD274, B7-H1) has been identified as the ligand for the immune inhibitory receptor programmed death 1 protein (PD1/PDCD1). PDL1 is a member of B7 family of immune molecules and this protein together with PDL2, are two ligands for PD1 expressed on activated lymphoid cells. By binding to PD1 on activated T cells, PDL1 may inhibit T cell responses by inducing apoptosis. Accordingly, it leads to the immune evasion of cancers and contribute to tumor growth, thus PDL1 is regarded as therapeutic target for malignant cancers. We selected PDL1 specific nanobodies from a high quality dromedary camel immune library by phage display technology, three anti-PDL1-VHHs were developed.

Keywords: Nanobody; Programmed death 1; Programmed death ligand 1; Tumor.

MeSH terms

  • Animals
  • B7-H1 Antigen / administration & dosage*
  • B7-H1 Antigen / immunology
  • Camelus / metabolism
  • Cell Surface Display Techniques
  • HEK293 Cells
  • Humans
  • Immunization
  • Neoplasms / drug therapy
  • Neoplasms / immunology*
  • Programmed Cell Death 1 Receptor / metabolism
  • Single-Domain Antibodies / metabolism*
  • Single-Domain Antibodies / pharmacology
  • Tumor Escape / drug effects

Substances

  • B7-H1 Antigen
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Single-Domain Antibodies